VAMG
VVOS icon

Voisard Asset Management Group’s Vivos Therapeutics VVOS Stock Holding History

Voisard Asset Management Group’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$3 – 655
2024
Q3 		$3 Buy
+1
New +$3 ﹤0.01% 715

Other funds holding VVOS

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Voisard Asset Management Group's VVOS Position: Q4 2024 in Review

Voisard Asset Management Group sold out of Vivos Therapeutics (VVOS) in Q4 2024, closing a stake of 1 share — an estimated $3 sold.

Voisard Asset Management Group first reported a position in VVOS in Q3 2024 and held it in 1 quarter. The position peaked at $3 in Q3 2024. 20 funds tracked by Wall St. Rank hold VVOS as of Q4 2024.

  • Voisard Asset Management Group reported no remaining Vivos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Voisard Asset Management Group sold 1 Vivos Therapeutics share in Q4 2024, an estimated $3.
  • Voisard Asset Management Group first reported a position in Vivos Therapeutics in Q3 2024 and held it in 1 quarter.
  • Voisard Asset Management Group's Vivos Therapeutics position peaked at $3 in Q3 2024.
  • 20 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2024.

Based on Voisard Asset Management Group's 13F filing for Q4 2024, filed 7 Feb 2025.